Aptevo Therapeutics INC Schedule 13G passive stakes

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed a Schedule 13G, reporting beneficial ownership of 6.3% of Aptevo Therapeutics Inc. common stock, primarily through exercisable warrants.

CVI Investments and Heights Capital Management have disclosed an 8.2% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through warrants.

Bank of America Corp /DE/ has filed an amended Schedule 13G, reporting beneficial ownership of 86 shares, representing 0.0% of Aptevo Therapeutics Inc.'s common stock.

Bank of America Corporation has disclosed a 15.0% beneficial ownership stake in Aptevo Therapeutics Inc. common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 9.1% passive ownership stake in Aptevo Therapeutics Inc.

L1 Capital Global Opportunities Master Fund, Ltd. reported a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc. common stock through warrants.

CVI Investments and Heights Capital Management disclose a 9.9% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.

A group of investment entities, led by YA II PN, Ltd., has disclosed a 9.99% beneficial ownership stake in Aptevo Therapeutics Inc., stemming from a new Standby Equity Purchase Agreement.

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have reported a 0.00% beneficial ownership stake in Aptevo Therapeutics Inc. as of June 25, 2025, down from approximately 9.8% on June 18, 2025, due to a significant share issuance by the company.

Bigger Capital Fund L P and its affiliates have significantly reduced their beneficial ownership in Aptevo Therapeutics Inc., falling below the 5% reporting threshold as of June 20, 2025.

L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a 9.95% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through common stock holdings.

L1 Capital Global Opportunities Master Fund, Ltd. has amended its Schedule 13G filing, reporting a substantial reduction in its beneficial ownership of Aptevo Therapeutics Inc. common stock.

A Schedule 13G filing reveals that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC currently hold 0% beneficial ownership in Aptevo Therapeutics Inc., following an initial potential ownership of 8.3% tied to a Securities Purchase Agreement.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 7.59% beneficial ownership stake in Aptevo Therapeutics Inc., holding 421,000 shares of common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 6.2% beneficial ownership stake in Aptevo Therapeutics Inc. through a Schedule 13G filing.

A recent Schedule 13G filing reveals that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, who briefly held a deemed 9.6% beneficial ownership in Aptevo Therapeutics Inc. on April 3, 2025, reported zero beneficial ownership as of April 9, 2025.

Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger have disclosed the sale of their entire 6.2% beneficial ownership in Aptevo Therapeutics Inc. common stock as of April 3, 2025.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 6.21% beneficial ownership stake in Aptevo Therapeutics Inc., holding 200,000 shares of common stock.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, disclosing a 4.99% passive beneficial ownership stake in Aptevo Therapeutics Inc., including shares issuable from warrants.

Hudson Bay Capital Management LP and Sander Gerber have reported a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through shares issuable upon warrant exercise, as of December 31, 2024.